abstract: The work aimed to isolate and characterise copia-like sequences from @entity0 . Thirty-two different @entity1 ( @entity1 ) sequences were isolated from a single oil palm genome using degenerate primers. Extreme sequence heterogeneity was observed. The DNA and protein sequences were assigned to three different classes (A, B, C) on the basis of bootstrapping. We estimated the copy number of the three different classes by using a dot-blot analysis. The comparative results suggest that class-B @entity1 sequences occur at a higher copy number in Cocos nucifera than in @entity0 and E. oleifera. Class-C @entity1 sequences, which comprise the bulk of isolated sequences, occur in much higher copy number in @entity0 than in Cocos nucifera, and E. oleifera. Class-A sequences, which have low copy number in @entity0 and Cocos nucifera, are not present in E. oleifera. Our preliminary results suggest that class-C sequences represent about 5% of the @entity0 genome, class B, 1% and class A, 0.1%. The methylation status of genomic domains specified by the @entity1 probes was analysed using two pairs of restriction enzymes, each pair having the same recognition sites but different methylation sensitivities ( MspI, HpaII and Sau3AI, MboI). Results from these experiments showed clearly that the genomic domains specified by the @entity1 probes are methylated. These also suggest that a higher copy number appears to correlate to a higher degree of methylation. Our preliminary results suggest that copia-like retrotransposons, because of their ubiquity and diversity, have great potential as genetic markers for plant genome and biodiversity analysis in @entity0 .

title: Characterisation of copia-like retrotransposons in oil palm ( XXXX .).

answer: @entity0


abstract: In contrast to shunt operation the indication for an endoscopic ventriculostomy in @entity0 diagnosed for normal pressure @entity3 is not scientifically established. From September 1997 to October 2001 we operated on 79 @entity0 diagnosed for normal pressure @entity3 . Diagnosis was established by means of the intrathecal lumbal or ventricular infusion test, the cerebrospinal fluid tap test and MRI-CSF flow studies pre- and post-operatively. In 60 @entity0 (76 %) we implanted a ventriculo-peritoneal shunt (Miethke @entity2 ), and in 15 @entity0 (19 %) we performed the endoscopic assisted third ventriculostomy. With our created NPH recovery rate and use of the clinical grading for normal pressure @entity3 created by Kiefer we compared the operative results of both @entity0 groups. Immediately after the operation the results are the same for both treatments. In the follow-up examination after 12 and 27 months @entity0 who underwent a ventriculostomy showed a better outcome, but the underdrainage rate was higher. Concerning the operation related complications the shunt treatment leaded to 10 revisions (17 %) because of four @entity1 (7 %), two @entity4 (3 %), two overdrainages (3 %), two catheter dislocations (3 %). The ventriculostomy leaded to one case with a pneumatocephalus (7 %) and one @entity5 (7 %). In both operation methods we saw cases of underdrainages, three after @entity2 (5 %) and two after ventriculostomy (13 %). In that @entity0 we performed a change of the implanted valve with a lower pressure level or rather an implantation of a valve system in the two cases who underwent a ventriculostomy. In @entity0 with a pathologically increased resistance to CSF outflow in the lumbal infusion test a shunt implantation with the Miethke @entity2 is indicated. @entity0 whose outflow resistance is increased in the ventricular infusion test are suspected for a functional interventricular stenosis and should be treated by means of an endoscopic assisted ventriculostomy.

title: [Shunt operation versus endoscopic ventriculostomy in normal pressure XXXX : diagnostics and outcome].

answer: @entity3


abstract: Potential treatments for @entity3 that have become resistant to standard chemotherapies include modulators of @entity1 cell survival, such as endothelin receptor (ETR) antagonist. We investigated the therapeutic efficacy of the dual ETR antagonist, @entity7 , on @entity0 @entity3 cells, SKOV3ip1 and IGROV1, growing orthotopically in @entity2 . @entity2 with established disease were treated with vehicle (control), @entity6 (weekly, intraperitoneal injections), @entity7 (daily oral administrations), or a combination of @entity6 and @entity7 . Treatment with @entity6 decreased @entity1 weight and volume of @entity5 . Combination therapy with @entity7 and @entity6 reduced @entity1 incidence and further reduced @entity1 weight and volume of @entity5 when compared with @entity6 alone. @entity7 alone occasionally reduced @entity1 weight but alone had no effect on @entity1 incidence or @entity5 . Immunohistochemical analyses revealed that treatment with @entity7 and @entity7 plus @entity6 inhibited the phosphorylation of ETRs and suppressed the survival pathways of @entity1 cells by decreasing the levels of pVEGFR2, pAkt, and pMAPK. The dose of @entity7 necessary for inhibition of phosphorylation correlated with the dose required to increase antitumor efficacy of @entity6 . Treatment with @entity7 enhanced the @entity4 mediated by @entity6 as measured by the degree of apoptosis in @entity1 cells and @entity1 -associated endothelial cells. Collectively, these results show that administration of @entity7 in combination with @entity6 prevents the progression of @entity3 in the peritoneal cavity of @entity2 in part by inhibiting survival pathways of both @entity1 cells and @entity1 -associated endothelial cells.

title: XXXX ( @entity7 ), a tissue-targeting endothelin receptor antagonist, enhances therapeutic efficacy of @entity6 by modulating survival pathways in orthotopic models of metastatic @entity0 @entity3 .

answer: @entity7


abstract: Potential treatments for @entity3 that have become resistant to standard chemotherapies include modulators of @entity1 cell survival, such as endothelin receptor (ETR) antagonist. We investigated the therapeutic efficacy of the dual ETR antagonist, @entity7 , on @entity0 @entity3 cells, SKOV3ip1 and IGROV1, growing orthotopically in @entity2 . @entity2 with established disease were treated with vehicle (control), @entity6 (weekly, intraperitoneal injections), @entity7 (daily oral administrations), or a combination of @entity6 and @entity7 . Treatment with @entity6 decreased @entity1 weight and volume of @entity5 . Combination therapy with @entity7 and @entity6 reduced @entity1 incidence and further reduced @entity1 weight and volume of @entity5 when compared with @entity6 alone. @entity7 alone occasionally reduced @entity1 weight but alone had no effect on @entity1 incidence or @entity5 . Immunohistochemical analyses revealed that treatment with @entity7 and @entity7 plus @entity6 inhibited the phosphorylation of ETRs and suppressed the survival pathways of @entity1 cells by decreasing the levels of pVEGFR2, pAkt, and pMAPK. The dose of @entity7 necessary for inhibition of phosphorylation correlated with the dose required to increase antitumor efficacy of @entity6 . Treatment with @entity7 enhanced the @entity4 mediated by @entity6 as measured by the degree of apoptosis in @entity1 cells and @entity1 -associated endothelial cells. Collectively, these results show that administration of @entity7 in combination with @entity6 prevents the progression of @entity3 in the peritoneal cavity of @entity2 in part by inhibiting survival pathways of both @entity1 cells and @entity1 -associated endothelial cells.

title: @entity7 ( XXXX ), a tissue-targeting endothelin receptor antagonist, enhances therapeutic efficacy of @entity6 by modulating survival pathways in orthotopic models of metastatic @entity0 @entity3 .

answer: @entity7


abstract: Potential treatments for @entity3 that have become resistant to standard chemotherapies include modulators of @entity1 cell survival, such as endothelin receptor (ETR) antagonist. We investigated the therapeutic efficacy of the dual ETR antagonist, @entity7 , on @entity0 @entity3 cells, SKOV3ip1 and IGROV1, growing orthotopically in @entity2 . @entity2 with established disease were treated with vehicle (control), @entity6 (weekly, intraperitoneal injections), @entity7 (daily oral administrations), or a combination of @entity6 and @entity7 . Treatment with @entity6 decreased @entity1 weight and volume of @entity5 . Combination therapy with @entity7 and @entity6 reduced @entity1 incidence and further reduced @entity1 weight and volume of @entity5 when compared with @entity6 alone. @entity7 alone occasionally reduced @entity1 weight but alone had no effect on @entity1 incidence or @entity5 . Immunohistochemical analyses revealed that treatment with @entity7 and @entity7 plus @entity6 inhibited the phosphorylation of ETRs and suppressed the survival pathways of @entity1 cells by decreasing the levels of pVEGFR2, pAkt, and pMAPK. The dose of @entity7 necessary for inhibition of phosphorylation correlated with the dose required to increase antitumor efficacy of @entity6 . Treatment with @entity7 enhanced the @entity4 mediated by @entity6 as measured by the degree of apoptosis in @entity1 cells and @entity1 -associated endothelial cells. Collectively, these results show that administration of @entity7 in combination with @entity6 prevents the progression of @entity3 in the peritoneal cavity of @entity2 in part by inhibiting survival pathways of both @entity1 cells and @entity1 -associated endothelial cells.

title: @entity7 ( @entity7 ), a tissue-targeting endothelin receptor antagonist, enhances therapeutic efficacy of XXXX by modulating survival pathways in orthotopic models of metastatic @entity0 @entity3 .

answer: @entity6


abstract: Potential treatments for @entity3 that have become resistant to standard chemotherapies include modulators of @entity1 cell survival, such as endothelin receptor (ETR) antagonist. We investigated the therapeutic efficacy of the dual ETR antagonist, @entity7 , on @entity0 @entity3 cells, SKOV3ip1 and IGROV1, growing orthotopically in @entity2 . @entity2 with established disease were treated with vehicle (control), @entity6 (weekly, intraperitoneal injections), @entity7 (daily oral administrations), or a combination of @entity6 and @entity7 . Treatment with @entity6 decreased @entity1 weight and volume of @entity5 . Combination therapy with @entity7 and @entity6 reduced @entity1 incidence and further reduced @entity1 weight and volume of @entity5 when compared with @entity6 alone. @entity7 alone occasionally reduced @entity1 weight but alone had no effect on @entity1 incidence or @entity5 . Immunohistochemical analyses revealed that treatment with @entity7 and @entity7 plus @entity6 inhibited the phosphorylation of ETRs and suppressed the survival pathways of @entity1 cells by decreasing the levels of pVEGFR2, pAkt, and pMAPK. The dose of @entity7 necessary for inhibition of phosphorylation correlated with the dose required to increase antitumor efficacy of @entity6 . Treatment with @entity7 enhanced the @entity4 mediated by @entity6 as measured by the degree of apoptosis in @entity1 cells and @entity1 -associated endothelial cells. Collectively, these results show that administration of @entity7 in combination with @entity6 prevents the progression of @entity3 in the peritoneal cavity of @entity2 in part by inhibiting survival pathways of both @entity1 cells and @entity1 -associated endothelial cells.

title: @entity7 ( @entity7 ), a tissue-targeting endothelin receptor antagonist, enhances therapeutic efficacy of @entity6 by modulating survival pathways in orthotopic models of metastatic @entity0 XXXX .

answer: @entity3


abstract: Potential treatments for @entity3 that have become resistant to standard chemotherapies include modulators of @entity1 cell survival, such as endothelin receptor (ETR) antagonist. We investigated the therapeutic efficacy of the dual ETR antagonist, @entity7 , on @entity0 @entity3 cells, SKOV3ip1 and IGROV1, growing orthotopically in @entity2 . @entity2 with established disease were treated with vehicle (control), @entity6 (weekly, intraperitoneal injections), @entity7 (daily oral administrations), or a combination of @entity6 and @entity7 . Treatment with @entity6 decreased @entity1 weight and volume of @entity5 . Combination therapy with @entity7 and @entity6 reduced @entity1 incidence and further reduced @entity1 weight and volume of @entity5 when compared with @entity6 alone. @entity7 alone occasionally reduced @entity1 weight but alone had no effect on @entity1 incidence or @entity5 . Immunohistochemical analyses revealed that treatment with @entity7 and @entity7 plus @entity6 inhibited the phosphorylation of ETRs and suppressed the survival pathways of @entity1 cells by decreasing the levels of pVEGFR2, pAkt, and pMAPK. The dose of @entity7 necessary for inhibition of phosphorylation correlated with the dose required to increase antitumor efficacy of @entity6 . Treatment with @entity7 enhanced the @entity4 mediated by @entity6 as measured by the degree of apoptosis in @entity1 cells and @entity1 -associated endothelial cells. Collectively, these results show that administration of @entity7 in combination with @entity6 prevents the progression of @entity3 in the peritoneal cavity of @entity2 in part by inhibiting survival pathways of both @entity1 cells and @entity1 -associated endothelial cells.

title: @entity7 ( @entity7 ), a tissue-targeting endothelin receptor antagonist, enhances therapeutic efficacy of @entity6 by modulating survival pathways in orthotopic models of metastatic XXXX @entity3 .

answer: @entity0


abstract: BACKGROUND: @entity2 is associated with characteristic symptoms of progressive @entity1 and regurgitation. As most @entity0 are elderly, the perioperative risk is usually high. We report our clinical experience with the transoral endoscopic staple-assisted method, including a thorough assessment of the symptomatic relief achieved by the procedure. METHODS: 46 consecutive @entity0 (29 m, 17 f) with a median age of 61 years (range, 37-96 years) were treated between 1997 and 2002. The symptoms and their frequency were registered. The follow-up consisted of clinical and radiographic investigations. RESULTS: The median size of the diverticulum was 4 cm (range, 2-12 cm). Transoral treatment was successful in 39 @entity0 ; in 7 cases (15.2%) a switch to open surgery was required. The median operating time was 30 min (range, 10-150 min). Mortality rate was nil, while morbidity was 7.7%. The median duration of the postoperative hospital stay was 5 days (range, 1-65 days). After a median follow-up of 11 months (range, 1-40 months), 5 @entity0 had been reoperated on endoscopically due to clinical recurrence. Clinical symptoms were significantly reduced ( @entity1 of liquids p <or= 0.0001, @entity1 of solids p <or= 0.001, regurgitation p <or= 0.001). CONCLUSION: Our results confirm that minimal invasive treatment of @entity2 is a safe method and provides significant symptomatic relief.

title: Significant symptomatic relief after transoral endoscopic staple-assisted treatment of XXXX .

answer: @entity2


abstract: OBJECTIVE: @entity1 ( @entity1 ) is a major cause of morbidity and mortality in neurosurgical @entity0 . Despite the overall poor prognosis a range in survival times exists. Many approaches have been undertaken to define @entity0 subgroups based on molecular changes. The aim of this study was to assess a possible correlation between the immunohistochemical @entity3 , @entity6 , @entity2 and @entity5 expression and age. METHOD: 143 @entity0 (77 male, 66 female) were included in this retrospective study who underwent craniotomy for newly-diagnosed @entity1 between May 1994 and February 2000. For statistical analysis, @entity0 were separated into three age groups: 1. < 40 years, 2. 40-60 years, 3. > 60 years. Immunohistochemical staining (IHC) was performed using anti- @entity3 (clone DO-1), anti- @entity6 (clone @entity7 ), anti- @entity2 (clone H11) and anti- @entity5 antibodies (clone AB-1). The results were compared with the Ki67/ @entity4 proliferation index (Ki67 PI) and @entity0 survival. FINDINGS: @entity3 protein expression was significantly decreasing with advanced age (p < 0.05) whereas @entity2 and @entity6 expression was increasing (p < 0.05; p=0.01). @entity5 expression was unrelated to age. Multivariate analysis revealed @entity5 protein expression as a significant predictor of prolonged survival (p=0.004) whereas @entity3 , @entity6 and @entity2 were not associated with @entity0 survival. @entity3 , @entity6 , @entity2 and @entity5 expression was not associated with the Ki67 PI. INTERPRETATION: Our results support the hypothesis that in @entity1 @entity0 a complex relationship exists between the @entity3 , @entity6 and @entity2 expression and age. @entity5 expression is not related to age. Notably, nuclear @entity5 expression turned out to be an independent prognostic indicator.

title: Age-related expression of XXXX , @entity6 , @entity2 and @entity5 in @entity1 multiforme.

answer: @entity3


abstract: OBJECTIVE: @entity1 ( @entity1 ) is a major cause of morbidity and mortality in neurosurgical @entity0 . Despite the overall poor prognosis a range in survival times exists. Many approaches have been undertaken to define @entity0 subgroups based on molecular changes. The aim of this study was to assess a possible correlation between the immunohistochemical @entity3 , @entity6 , @entity2 and @entity5 expression and age. METHOD: 143 @entity0 (77 male, 66 female) were included in this retrospective study who underwent craniotomy for newly-diagnosed @entity1 between May 1994 and February 2000. For statistical analysis, @entity0 were separated into three age groups: 1. < 40 years, 2. 40-60 years, 3. > 60 years. Immunohistochemical staining (IHC) was performed using anti- @entity3 (clone DO-1), anti- @entity6 (clone @entity7 ), anti- @entity2 (clone H11) and anti- @entity5 antibodies (clone AB-1). The results were compared with the Ki67/ @entity4 proliferation index (Ki67 PI) and @entity0 survival. FINDINGS: @entity3 protein expression was significantly decreasing with advanced age (p < 0.05) whereas @entity2 and @entity6 expression was increasing (p < 0.05; p=0.01). @entity5 expression was unrelated to age. Multivariate analysis revealed @entity5 protein expression as a significant predictor of prolonged survival (p=0.004) whereas @entity3 , @entity6 and @entity2 were not associated with @entity0 survival. @entity3 , @entity6 , @entity2 and @entity5 expression was not associated with the Ki67 PI. INTERPRETATION: Our results support the hypothesis that in @entity1 @entity0 a complex relationship exists between the @entity3 , @entity6 and @entity2 expression and age. @entity5 expression is not related to age. Notably, nuclear @entity5 expression turned out to be an independent prognostic indicator.

title: Age-related expression of @entity3 , @entity6 , @entity2 and @entity5 in XXXX multiforme.

answer: @entity1


abstract: OBJECTIVE: @entity1 ( @entity1 ) is a major cause of morbidity and mortality in neurosurgical @entity0 . Despite the overall poor prognosis a range in survival times exists. Many approaches have been undertaken to define @entity0 subgroups based on molecular changes. The aim of this study was to assess a possible correlation between the immunohistochemical @entity3 , @entity6 , @entity2 and @entity5 expression and age. METHOD: 143 @entity0 (77 male, 66 female) were included in this retrospective study who underwent craniotomy for newly-diagnosed @entity1 between May 1994 and February 2000. For statistical analysis, @entity0 were separated into three age groups: 1. < 40 years, 2. 40-60 years, 3. > 60 years. Immunohistochemical staining (IHC) was performed using anti- @entity3 (clone DO-1), anti- @entity6 (clone @entity7 ), anti- @entity2 (clone H11) and anti- @entity5 antibodies (clone AB-1). The results were compared with the Ki67/ @entity4 proliferation index (Ki67 PI) and @entity0 survival. FINDINGS: @entity3 protein expression was significantly decreasing with advanced age (p < 0.05) whereas @entity2 and @entity6 expression was increasing (p < 0.05; p=0.01). @entity5 expression was unrelated to age. Multivariate analysis revealed @entity5 protein expression as a significant predictor of prolonged survival (p=0.004) whereas @entity3 , @entity6 and @entity2 were not associated with @entity0 survival. @entity3 , @entity6 , @entity2 and @entity5 expression was not associated with the Ki67 PI. INTERPRETATION: Our results support the hypothesis that in @entity1 @entity0 a complex relationship exists between the @entity3 , @entity6 and @entity2 expression and age. @entity5 expression is not related to age. Notably, nuclear @entity5 expression turned out to be an independent prognostic indicator.

title: Age-related expression of @entity3 , @entity6 , XXXX and @entity5 in @entity1 multiforme.

answer: @entity2


abstract: OBJECTIVE: @entity1 ( @entity1 ) is a major cause of morbidity and mortality in neurosurgical @entity0 . Despite the overall poor prognosis a range in survival times exists. Many approaches have been undertaken to define @entity0 subgroups based on molecular changes. The aim of this study was to assess a possible correlation between the immunohistochemical @entity3 , @entity6 , @entity2 and @entity5 expression and age. METHOD: 143 @entity0 (77 male, 66 female) were included in this retrospective study who underwent craniotomy for newly-diagnosed @entity1 between May 1994 and February 2000. For statistical analysis, @entity0 were separated into three age groups: 1. < 40 years, 2. 40-60 years, 3. > 60 years. Immunohistochemical staining (IHC) was performed using anti- @entity3 (clone DO-1), anti- @entity6 (clone @entity7 ), anti- @entity2 (clone H11) and anti- @entity5 antibodies (clone AB-1). The results were compared with the Ki67/ @entity4 proliferation index (Ki67 PI) and @entity0 survival. FINDINGS: @entity3 protein expression was significantly decreasing with advanced age (p < 0.05) whereas @entity2 and @entity6 expression was increasing (p < 0.05; p=0.01). @entity5 expression was unrelated to age. Multivariate analysis revealed @entity5 protein expression as a significant predictor of prolonged survival (p=0.004) whereas @entity3 , @entity6 and @entity2 were not associated with @entity0 survival. @entity3 , @entity6 , @entity2 and @entity5 expression was not associated with the Ki67 PI. INTERPRETATION: Our results support the hypothesis that in @entity1 @entity0 a complex relationship exists between the @entity3 , @entity6 and @entity2 expression and age. @entity5 expression is not related to age. Notably, nuclear @entity5 expression turned out to be an independent prognostic indicator.

title: Age-related expression of @entity3 , @entity6 , @entity2 and XXXX in @entity1 multiforme.

answer: @entity5


abstract: OBJECTIVE: @entity1 ( @entity1 ) is a major cause of morbidity and mortality in neurosurgical @entity0 . Despite the overall poor prognosis a range in survival times exists. Many approaches have been undertaken to define @entity0 subgroups based on molecular changes. The aim of this study was to assess a possible correlation between the immunohistochemical @entity3 , @entity6 , @entity2 and @entity5 expression and age. METHOD: 143 @entity0 (77 male, 66 female) were included in this retrospective study who underwent craniotomy for newly-diagnosed @entity1 between May 1994 and February 2000. For statistical analysis, @entity0 were separated into three age groups: 1. < 40 years, 2. 40-60 years, 3. > 60 years. Immunohistochemical staining (IHC) was performed using anti- @entity3 (clone DO-1), anti- @entity6 (clone @entity7 ), anti- @entity2 (clone H11) and anti- @entity5 antibodies (clone AB-1). The results were compared with the Ki67/ @entity4 proliferation index (Ki67 PI) and @entity0 survival. FINDINGS: @entity3 protein expression was significantly decreasing with advanced age (p < 0.05) whereas @entity2 and @entity6 expression was increasing (p < 0.05; p=0.01). @entity5 expression was unrelated to age. Multivariate analysis revealed @entity5 protein expression as a significant predictor of prolonged survival (p=0.004) whereas @entity3 , @entity6 and @entity2 were not associated with @entity0 survival. @entity3 , @entity6 , @entity2 and @entity5 expression was not associated with the Ki67 PI. INTERPRETATION: Our results support the hypothesis that in @entity1 @entity0 a complex relationship exists between the @entity3 , @entity6 and @entity2 expression and age. @entity5 expression is not related to age. Notably, nuclear @entity5 expression turned out to be an independent prognostic indicator.

title: Age-related expression of @entity3 , XXXX , @entity2 and @entity5 in @entity1 multiforme.

answer: @entity6


abstract: A simple and sensitive reversed-phase liquid chromatography method was developed and validated for the determination of @entity4 (NC) in @entity0 plasma. @entity4 and @entity5 , used as internal standard, were initially extracted from plasma by a rapid solid-phase extraction using C(18) cartridges. After extraction, @entity4 was separated by HPLC on a C(18) column and quantified by ultraviolet detection at 254 nm. A mixture of @entity3 -0.02 M @entity6 buffer- @entity2 (45:40:15) with 0.2% of @entity1 of pH of 6.1 was used as mobile phase. The mean (+/-SD) extraction efficiency of NC was 77.56 +/- 5.4, 84.23 +/- 4.32 and 83.94 +/- 3.87% for drug concentrations of 5, 25 and 100 ng/mL, respectively. The method proved to be linear in the range of 5-100 ng/mL with a regression coefficient of 0.9993. The relative standard deviations of intra- and inter-day analysis for NC in plasma were 3.26-6.52% (n = 5) and 4.71-9.38% (n = 5), respectively. The differences of the mean value measured from the concentration prepared, expressed in percentages (bias percentage), were only - 5.2, 0.4 and 0.8% at NC 5, 25 and 50 ng/mL, which confirmed the accuracy of the method. The analytical technique was used to determine NC plasma concentration after drug oral administration to @entity0 . The results inferred that NC is rapidly absorbed in @entity0 and has a short half-life (t(1/2) = 1.34 h).

title: A simple method for XXXX quantification in plasma using solid-phase extraction and reversed-phase high-performance liquid chromatography.

answer: @entity4


abstract: AIMS OF THE STUDY: @entity6 ( @entity6 ) is a @entity7 manifesting as @entity3 , recurrent @entity4 , @entity2 with marked heterogeneity in clinical presentation. The objective was to study the clinical spectrum of the disorder in India. METHODOLOGY: We studied 50 @entity6 @entity0 and followed them for up to six years (Age range 2-47 years). RESULTS: The presenting features were @entity4 35 out of 50, @entity3 30 out of 50 (requiring blood transfusion in 25). @entity2 was found in all @entity0 . @entity5 was found in all @entity0 whereas spherocytes were found in only 19 out of 42 @entity0 . Reduced red cell survival was noted in 9/12 @entity0 studied with 51Cr labeled RBCs. There was a definite improvement in the hemoglobin values in those who underwent splenectomy. Thirteen cases had similarly affected family member/s. Fifteen of the cases had family history consistent with @entity1 ( @entity1 ) inheritance (eight families) while in six cases (5 families), inheritance was likely to be autosomal recessive (AR). There was intrafamilial variability in the age of presentation in the @entity1 families. CONCLUSIONS: Our results suggest that both @entity1 and recessive patterns of @entity6 are seen in India and the clinical profile of the Indian @entity6 @entity0 is similar to that described in other populations. @entity6 presenting in childhood is also not uncommon. However, the predominant underlying protein defect in Indian @entity0 needs to be characterized.

title: Clinical profile of XXXX .

answer: @entity6


abstract: Telomerase is a reverse transcriptase which helps to stabilize the length of telomeres by adding TTAGGG repeats onto the telomeres that enables unlimited division of the cell. Absence of telomerase activity causes replication senescence and cell death. Activity of telomerase was detected in embryonal, gonadal and @entity1 cells, but was not detected in adult somatic tissues with the exception of tissues containing stem cells. Telomerase inhibitors are being considered as potential anticancer drugs with the hope that the lack of telomerase expression in normal somatic cells would result in a higher specific therapy with fewer side effects than conventional chemotherapy. Because of high activity of telomerase in gonadal cells, we hypothesized that one of the drugs which selectively interfere with spermatogenesis may act like a telomerase inhibitor. @entity4 is a male contraceptive derived from @entity3 seeds. It causes suppression of spermatogenesis by an unknown mechanism. It has a non-endocrine inhibiting effect on spermatogenesis, gradual onset of action, and irreversible suppression of spermatogenesis with increasing length of use. It also has an antiproliferative effect on cell lines derived from @entity1 , mild antineoplastic action in vivo with few side effects. It has mild inhibiting influence on the replication of @entity2 via possible inhibition of reverse transcriptase @entity2 . This shows its possible telomerase inhibiting activity. It appears that @entity4 is a potential new drug for @entity1 therapy, because of its spermatotoxic and cytotoxic activity on cell lines derivided from @entity1 . We posit that the use of @entity4 in combination with other anticancer chemotherapeutics can lead to a more effective therapy of @entity0 @entity1 . (Ref. 47.).

title: Telomerase inhibitors in anticancer therapy: XXXX as a potential telomerase inhibitor.

answer: @entity4


abstract: BACKGROUND: @entity0 diagnosis as penil @entity2 and treated with surgical methods were evaluated retrospectively between January 1990-February 2002. METHODS: @entity0 were evaluated by age, @entity1 type, time passed after the @entity1 , physical examination and radiologic data. RESULTS: The cause of @entity1 was @entity1 in all @entity0 . 14 @entity1 (60.8%) were during sexual activity, 6 @entity1 (26%) were during handling the erective penis in morning erection, 3 of @entity1 (13%) were due to the rolling on to the penis. @entity3 was seen in 1 @entity0 and microscopic @entity4 was detected in 5 @entity0 . Subcoronal circular incision was carried out in 16 @entity0 (69.5%), semicircular incision was done directly on the injury in 6 @entity0 (26%) and from penis radix to scrotum was done in 1 @entity0 (4.3%). There was unilateral corpus cavernosum injury in 21 @entity0 . Bilateral corpus cavernosum injury in 1 @entity0 , corpuscavernosum, corpus spongiosum and @entity1 in 1 @entity0 . @entity5 was detected only in 2 @entity0 at postoperatively early period. After evaluating 20 @entity0 with medical history and physical examination in postoperative control penil curvature permitting sexual activity was detected in 3 @entity0 . CONCLUSION: We concluded that @entity0 with penil @entity2 may be treated with low complication rate by early surgical procedure.

title: [Surgical treatment of penil XXXX ].

answer: @entity2


abstract: In central nervous system (CNS) tissue preparations, wild-type @entity3 ( @entity4 ) mainly infects neurons, and in vivo it causes lethal @entity1 in neonatal and adult rodents. The @entity4 A7(74), by contrast, is avirulent in adult rodents, triggering only limited CNS @entity2 . To examine A7(74) @entity2 in hippocampal tissue, the authors constructed a replicon, termed @entity4 (A774nsP)-GFP, expressing green fluorescent protein. The results were compared to replication-proficient recombinant A7(74) encoding GFP, named VA7-EGFP. As nonstructural gene mutations can confer temperature sensitivity, the authors also tested whether @entity2 was temperature-dependent. Indeed, at 31 degrees C both viral recombinants transduced significantly more baby hamster kidney cells than at 37 degrees C. When @entity0 hippocampal slices and dissociated cells were incubated at 37 degrees C, @entity4 (A774nsP)-GFP transduced glial cells but virtually no neurons-the opposite of conventional @entity4 . For VA7-EGFP at 37 degrees C, the preferred GFP-positive cells in hippocampal slices were also non-neuronal cells. At 31 degrees C, however, a more wild-type phenotype was found, with 33% and 94% of the GFP-positive cells being neurons for @entity4 (A774nsP)-GFP in slices and dissociated cells, respectively, and 94% neurons for VA7-EGFP in slices. Immunochemical and electrophysiological analyses confirmed that at 37 degrees C virtually all cells transduced by @entity4 (A774nsP)-GFP in slices were astrocytes, while at 31 degrees C they also contained neurons. These results show that in addition to the developmental age, the temperature determines which cell type becomes infected by A7(74). Our data suggest that A7(74) is avirulent in adult animals because it does not readily replicate in mature neurons at body temperature, whereas it still does so at lower temperatures.

title: XXXX A7(74) transduces hippocampal neurons and glial cells in a temperature-dependent dual manner.

answer: @entity3


abstract: @entity13 ( @entity13 ) is an @entity7 caused by the Gram-positive bacteria @entity12 following an untreated @entity2 in susceptible @entity0 . @entity14 ( @entity14 ), the most serious complication, occurs in 30-45% of @entity13 @entity0 and leads to chronic @entity4 . Here, we focus on the genes that confer susceptibility for developing this disease. Molecular mimicry mediates the cross-reactions between streptococcal antigens and @entity0 proteins. Several autoantigens have been identified, including cardiac @entity15 , @entity9 , and other intracellular proteins. In heart tissue, antigen-driven oligoclonal T cell expansions probably cause the @entity14 . These cells are @entity6 + and produce inflammatory cytokines ( @entity3 and @entity5 ). @entity11 + cells are found in the myocardium; however, these cells are very scarce in the @entity4 of @entity14 @entity0 . @entity11 is a Th2-type cytokine and plays a regulatory role in the inflammatory response mediated by @entity8 cytokines. Our findings indicate that the @entity8 /Th2 cytokine balance has a role in healing @entity10 while the low numbers of @entity11 -producing cells in the valves probably induced the progressive and permanent @entity1 .

title: XXXX : mediation by complex immune events.

answer: @entity14


abstract: BACKGROUND: @entity1 is a frequently observed condition, but its optimal management continues to be debated. OBJECTIVE: The goal of this study was to evaluate the available guidelines, developed at the national level, for the management of @entity1 in Western countries, with a focus on their differences. METHODS: A literature search was conducted of the Cochrane Library, EMBASE, TRIP, and MEDLINE databases from their inception (1993 for the Cochrane Library, 1980 for EMBASE, 1997 for TRIP, and 1966 for MEDLINE) through April 25, 2010. The following search terms were used: @entity6 , sore throat, @entity5 , pharyngotonsillitis, @entity2 , Group A b-haemolytic @entity2 , and @entity1 . Searches were limited to type of article or document (practice guideline or guideline) with no language restrictions or language limits. RESULTS: Twelve national guidelines were identified: 6 from European countries (France, United Kingdom, Finland, Holland, Scotland, and Belgium), 5 from the United States, and 1 from Canada. Recommendations differ substantially with regard to the use of a rapid antigen diagnostic test or throat culture and the indications for antibiotic treatment. The North American, Finnish, and French guidelines recommend performing one timely microbiologic investigation in suspected cases, and prescribing antibiotics in confirmed cases to prevent suppurative complications and @entity4 . According to the remaining European guidelines, however, acute sore throat is considered a benign, self-limiting disease. Microbiologic tests are not routinely recommended by these latter guidelines, and antibiotic treatment is reserved for well-selected cases. The use of the Centor score, for evaluation of the risk of @entity1 , is recommended by several guidelines, but subsequent decisions on the basis of the results differ in terms of which subjects should undergo microbiologic investigation. All guidelines agree that narrow-spectrum penicillin is the first choice of antibiotic for the treatment of @entity1 and that treatment should last for 10 days to eradicate the microorganism. Once-daily @entity0 was recommended by 2 US guidelines as equally effective. CONCLUSION: The present review found substantial discrepancies in the recommendations for the management of @entity6 among national guidelines in @entity3 .

title: Analysis of different recommendations from international guidelines for the management of acute XXXX in adults and children.

answer: @entity6


abstract: UNASSIGNED: The objective of this series of studies was to investigate the effects of inflammatory diseases occurring before breeding on the developmental biology and reproductive responses in dairy @entity3 . Data from 5 studies were used to investigate different questions associating health status before breeding and reproductive responses. Health information for all studies was composed of the incidence of retained fetal membranes, metritis, @entity6 , @entity7 , and respiratory and digestive problems from parturition until the day of breeding. @entity5 and metritis were grouped as @entity8 ( @entity8 ). @entity6 , @entity7 , digestive and respiratory problems were grouped as nonuterine diseases (NUTD). Study 1 evaluated the effect of disease before artificial insemination (AI), anovulation before synchronization of the estrous cycle, and low body condition score at AI on pregnancy per AI, as well as their potential interactions or additive effects. Study 2 investigated the effect of site of @entity0 ( @entity8 vs. NUTD) and time of occurrence relative to preantral or antral stages of ovulatory follicle development, and the effect of @entity8 and NUTD on fertility responses of @entity3 bred by AI or by embryo transfer. Study 3 evaluated the effect of disease on fertilization and embryonic development to the morula stage. Study 4 evaluated the effect of disease on preimplantation conceptus development as well as secretion of IFN-   and transcriptome. Study 5 investigated the effect of diseases before AI on the transcript expression of interferon-stimulated genes in peripheral blood leukocytes during peri-implantation stages of conceptus development after first AI postpartum. Altogether, these studies demonstrated that @entity0 before breeding reduced fertilization of oocytes and development to morula, and @entity2 development to elongation stages and secretion of IFN-   in the uterine lumen. @entity1 caused @entity0 -like changes in transcriptome of conceptus cells, increased risk of @entity4 , and reduced pregnancy or calving per breeding. Moreover, the effects on reproduction were independent of cyclic status before synchronization of the estrous cycle and body condition score at breeding, which all had additive negative effects on fertility of dairy @entity3 . Occurrence of disease at preantral or at antral stages of ovulatory follicle development had similar detrimental effects on pregnancy results. The carryover effects of diseases on developmental biology might last longer than 4 mo. Reduced oocyte competence is a likely reason for carryover effects of diseases on developmental biology, but impaired uterine environment was also shown to be involved.

title: Carryover effect of postpartum inflammatory diseases on developmental biology and fertility in lactating dairy XXXX .

answer: @entity3


abstract: OBJECTIVE: To assess the association of the Mayo Adhesive Probability (MAP) score and progression-free survival (PFS) in @entity0 with @entity3 ( @entity3 ). The MAP score is derived from cross-sectional imaging measurements of perinephric fat thickness and stranding. MATERIALS AND METHODS: We identified 456 @entity0 from a prospective registry who were treated surgically for localized @entity3 between 2002 and 2014. One reviewer calculated a preoperative MAP score (0-5) for each @entity0 . Kaplan-Meier curves were utilized to estimate PFS. Cox proportional hazard models were used to estimate the association of MAP score with risk of progression univariately and after adjusting for covariates such as age, body mass index (BMI), and size, stage, grade, @entity2 scores. RESULTS: @entity0 with higher MAP scores (4-5) were more likely to be male, to be older, to have higher BMI, and to have @entity1 (all P   <.01). Of our total cohort, 405 @entity0 had MAP scores and follow-up data to assess PFS. Dichotomizing MAP scores into high (MAP 4-5) and low (MAP 0-3) yields a hazard ratio of 2.16 for the 4-5 group vs 0-3 (95% confidence interval: 1.15-4.06, P   =   .017). Adjustment for BMI did not alter the association (BMI-adjusted hazard ratio [HR] =   2.20 [1.07-4.52], P   =   .032). Of interest, the association with MAP and PFS remains for @entity4 @entity3 @entity0 (n   =   287, HR   =   3.46 [1.06-11.24], P   =   .039). CONCLUSION: High MAP scores (4-5) are associated with decreased PFS in @entity0 surgically treated for clinically localized @entity3 compared with @entity0 with lower MAP scores (0-3). @entity3 may be associated with perinephric fat thickness and stranding.

title: Mayo Adhesive Probability Score Is Associated With XXXX Progression-free Survival.

answer: @entity3


abstract: OBJECTIVE: Treatment of extremely large @entity4 ( @entity3 ) remains challenging. Although volume-staged stereotactic radiosurgery (SRS) is a possible multimodal treatment option for such lesions, reports of these procedures are scarce. In this study, we evaluated the efficacy and safety of volume-staged SRS in @entity0 with @entity3 >20 cm(3) with more than 3 years of follow-up. MEHODS: Between 2005 and 2012, 18 @entity0 with AVMs >20 cm(3) were treated by volume-staged SRS. The median target volume was 38 cm(3) (interquartile range, IQR, 31-53 cm(3)). Treatment was 2-3 staged with a median 6 months interval. RESULTS: The median follow up period from last SRS treatment was 53 months (IQR, 41-75 months). @entity2 was achieved in 6 @entity0 (33%), and the obliteration rate at 5 years after initial SRS was 35% by the Kaplan-Meier method. The annual @entity1 rate after last SRS treatment was 3.9% (95% confidence interval, 0.8-11.5%). Two @entity0 experienced radiation-induced adverse effects. CONCLUSINOS: In our series, volume-staged SRS for @entity3 > 20cm(3) achieved nidus obliteration at the rate of 35% at 5 years. There was still a high risk for @entity1 (approximately 4 % / year) after treatment, which seemed to be higher than the rate observed in common post-treatment course of single-session SRS for @entity3 with average size. Further cases will help determine whether this challenging treatment method could be regularly considered, based on its efficacy and risks, including comparison with the natural history of large AVMs.

title: Outcomes of volume-staged radiosurgery for cerebral XXXX larger than 20cm3 with more than 3years of follow-up.

answer: @entity3


abstract: OBJECTIVE: To design and validate a questionnaire to assess the level of knowledge regarding @entity1 in college students. DESIGN: Observational, prospective, and longitudinal study, with the design of the questionnaire based on a conceptual review and validation by a cognitive pre-test and pilot test-retest, with analysis of the psychometric properties in each application. LOCATION: University Foundation of Bages, Barcelona. @entity2 community care. @entity0 : A total of 140 students from Health Sciences; 53 @entity0 and 87 @entity0 with a mean age of 21.87 years; 28 participated in the pre-test and 112 in the test-retests, 110 students completed the study. MAIN MEASUREMENTS: Validity and stability study using Cronbach a and Pearson product-moment correlation coefficient statistics; relationship skills with sex and type of study, non-parametric statistical Mann-Whitney and Kruskal-Wallis tests; for demographic variables, absolute or percentage frequencies, as well as mean, central tendency and standard deviation as measures of dispersion were calculated. The statistical significance level was 95% confidence. RESULTS: The questionnaire was obtained that had 10 questions divided into four dimensions (classification, demographics characteristics of @entity0 , risk factors and clinical manifestations of @entity1 ). The scale showed good internal consistency in its final version (Cronbach a=0.724) and adequate stability (Pearson correlation 0.749). CONCLUSIONS: The designed tool can be accurately used to assess Health Sciences students' knowledge of @entity1 .

title: [Design and validation of a questionnaire to assess the level of general knowledge on XXXX in students of Health Sciences].

answer: @entity1


abstract: UNASSIGNED: High intensity exercise is associated with several potentially thrombogenic risk factors, including dehydration and hemoconcentration, vascular @entity5 , @entity3 , @entity1 , long-distance travel, and contraceptive usage. These are well documented in case reports of @entity2 in track and field @entity12 . For mountaineers and those working at high altitude, additional risks exist. However, despite there being a high degree of vigilance for "classic" conditions encountered at altitude (eg, @entity17 , @entity14 , and high altitude @entity13 ), mainstream @entity15 regarding thrombotic conditions and their complications in mountain @entity12 is relatively low. This is significant because @entity8 events (including @entity9 , @entity10 , and @entity18 ) are not uncommon at altitude. We describe a case of @entity9 and @entity10 in a male mountain guide and discuss the diagnostic issues encountered by his medical practitioners. Potential risk factors affecting blood circulation (eg, seated car travel and compression of popliteal vein) and @entity11 (eg, @entity6 , environmental and psychological stressors [avalanche risk, extreme cold]) relevant to the subject of this report and mountain @entity12 in general are identified. Considerations for mitigating and managing @entity7 in addition to personalized care planning at altitude are discussed. The prevalence of @entity7 in mountain @entity12 is uncharted, but lowlanders increasingly go to high altitude to @entity19 , @entity4 , or climb. @entity16 can and do occur in physically active @entity0 , and @entity7 prevention and recognition will demand heightened @entity15 among @entity0 , healthcare practitioners, and the altitude sport/leisure industry at large.

title: @entity9 and XXXX in a Mountain Guide: Awareness, Diagnostic Challenges, and Management Considerations at Altitude.

answer: @entity10


abstract: UNASSIGNED: High intensity exercise is associated with several potentially thrombogenic risk factors, including dehydration and hemoconcentration, vascular @entity5 , @entity3 , @entity1 , long-distance travel, and contraceptive usage. These are well documented in case reports of @entity2 in track and field @entity12 . For mountaineers and those working at high altitude, additional risks exist. However, despite there being a high degree of vigilance for "classic" conditions encountered at altitude (eg, @entity17 , @entity14 , and high altitude @entity13 ), mainstream @entity15 regarding thrombotic conditions and their complications in mountain @entity12 is relatively low. This is significant because @entity8 events (including @entity9 , @entity10 , and @entity18 ) are not uncommon at altitude. We describe a case of @entity9 and @entity10 in a male mountain guide and discuss the diagnostic issues encountered by his medical practitioners. Potential risk factors affecting blood circulation (eg, seated car travel and compression of popliteal vein) and @entity11 (eg, @entity6 , environmental and psychological stressors [avalanche risk, extreme cold]) relevant to the subject of this report and mountain @entity12 in general are identified. Considerations for mitigating and managing @entity7 in addition to personalized care planning at altitude are discussed. The prevalence of @entity7 in mountain @entity12 is uncharted, but lowlanders increasingly go to high altitude to @entity19 , @entity4 , or climb. @entity16 can and do occur in physically active @entity0 , and @entity7 prevention and recognition will demand heightened @entity15 among @entity0 , healthcare practitioners, and the altitude sport/leisure industry at large.

title: XXXX and @entity10 in a Mountain Guide: Awareness, Diagnostic Challenges, and Management Considerations at Altitude.

answer: @entity9


abstract: UNASSIGNED: Nebulized antimicrobial agents are increasingly administered for treatment of @entity2 in mechanically ventilated (MV) @entity0 . A structured online questionnaire assessing the indications, dosages and recent patterns of use for nebulized antimicrobial agents in MV @entity0 was developed. The questionnaire was distributed worldwide and completed by 192 intensive care units. The most common indications for using nebulized antimicrobial agent were @entity3 ( @entity3 ; 58/87), @entity3 ( @entity3 ; 56/87) and management of multidrug-resistant, Gram-negative (67/87) bacilli in the respiratory tract. The most common prescribed nebulized agents were @entity6 and @entity1 (36/87, 41.3% and 24/87, 27.5%), @entity4 (32/87, 36.7%) and @entity5 (23/87, 26.4%). @entity6 , @entity5 and @entity4 daily doses for @entity3 were significantly higher than for @entity3 (p  <  0.05). Combination of parenteral and nebulized antibiotics occurred in 50 (86%) of 58 prescriptions for @entity3 and 36 (64.2%) of 56 of prescriptions for @entity3 . The use of nebulized antimicrobial agents in MV @entity0 is common. There is marked heterogeneity in clinical practice, with significantly different in use between @entity0 with @entity3 and @entity3 . Randomized controlled clinical trials and international guidance on indications, dosing and antibiotic combinations to improve clinical outcomes are urgently required.

title: Global survey on nebulization of antimicrobial agents in mechanically ventilated XXXX : a call for international guidelines.

answer: @entity0


abstract: OBJECTIVES: To evaluate marginal adaptation, @entity1 load and failure types of CAD/ @entity2 polymeric inlays. METHODS: Standardized prepared @entity0 molars (48) were divided into four groups (n=12): (A) PCG (positive control group); adhesively luted glass-ceramic inlays, (B) @entity4 ; CAD/ @entity2 polymeric inlays luted using a self-adhesive resin cement, (C) @entity3 ; CAD/ @entity2 polymeric inlays luted using a conventional resin cement, and (D) NCG (negative control group); direct-filled resin-based composite restorations. All specimens were subjected to a chewing simulator. Before and after chewing fatigue, marginal adaptation was assessed at two interfaces: (1) between dental hard tissues and luting cement and (2) between luting cement and restoration. Thereafter, the specimens were loaded and the @entity1 loads, as well as the failure types, were determined. The data were analysed using three- and one-way ANOVA with post hoc Scheff   test, two sample Student's t-test (p<0.05). RESULTS: Before and after chewing fatigue, marginal adaptation for interface 1 showed significantly better results for @entity4 and PCG than for @entity3 (p=0.001-0.02) and NCG (p=0.001-0.047). For interface 2, marginal adaptation for @entity3 was significantly inferior to @entity4 (p<0.001) and PCG (p<0.001). Chewing fatigue had a negative impact on the marginal adaptation of @entity3 and NCG. No significant differences in @entity1 load were found between all tested groups. SIGNIFICANCE: Self-adhesive luted polymeric CAD/ @entity2 inlays showed similar marginal adaptation and @entity1 load values compared to adhesively luted glass-ceramic inlays.

title: Marginal adaptation, @entity1 load and macroscopic failure mode of adhesively luted PMMA-based CAD/ XXXX inlays.

answer: @entity2


abstract: OBJECTIVES: To evaluate marginal adaptation, @entity1 load and failure types of CAD/ @entity2 polymeric inlays. METHODS: Standardized prepared @entity0 molars (48) were divided into four groups (n=12): (A) PCG (positive control group); adhesively luted glass-ceramic inlays, (B) @entity4 ; CAD/ @entity2 polymeric inlays luted using a self-adhesive resin cement, (C) @entity3 ; CAD/ @entity2 polymeric inlays luted using a conventional resin cement, and (D) NCG (negative control group); direct-filled resin-based composite restorations. All specimens were subjected to a chewing simulator. Before and after chewing fatigue, marginal adaptation was assessed at two interfaces: (1) between dental hard tissues and luting cement and (2) between luting cement and restoration. Thereafter, the specimens were loaded and the @entity1 loads, as well as the failure types, were determined. The data were analysed using three- and one-way ANOVA with post hoc Scheff   test, two sample Student's t-test (p<0.05). RESULTS: Before and after chewing fatigue, marginal adaptation for interface 1 showed significantly better results for @entity4 and PCG than for @entity3 (p=0.001-0.02) and NCG (p=0.001-0.047). For interface 2, marginal adaptation for @entity3 was significantly inferior to @entity4 (p<0.001) and PCG (p<0.001). Chewing fatigue had a negative impact on the marginal adaptation of @entity3 and NCG. No significant differences in @entity1 load were found between all tested groups. SIGNIFICANCE: Self-adhesive luted polymeric CAD/ @entity2 inlays showed similar marginal adaptation and @entity1 load values compared to adhesively luted glass-ceramic inlays.

title: Marginal adaptation, XXXX load and macroscopic failure mode of adhesively luted PMMA-based CAD/ @entity2 inlays.

answer: @entity1


abstract: In this study, we included 236 @entity0 with @entity1 and ejection fraction (EF) <35% who underwent surgical treatment. @entity0 were randomized in two groups. There were 116 @entity0 who underwent coronary artery bypass grafting (CABG) with surgical ventricular reconstruction (SVR) and 120 @entity0 who underwent CABG alone. The hospital mortality rate was 5.8% after isolated CABG and 3.5% after CABG combined with SVR. All survivors had follow-up investigation from four months to five years, with a mean follow-up time of 31  13 months. The mean New York Heart Association (NYHA) functional class decreased from 2.9  0.5 to 2.2  0.7 one year after CABG and from 3.1  0.4 to 2.0  0.6 one year after CABG with SVR. We showed that left ventricular reconstruction significantly decreased EDV from 237  52 to 176  30 and correspondingly increased EF from 32  6 to 39  9. However, after isolated CABG EF did not increase significantly (32  7 preoperatively and 34  11 postoperatively). One- and three-year rates were 95% and 78% after SVR with CABG and 83% and 78% after CABG alone. Despite the more aggressive surgical strategy, left ventricular reconstruction did not increase operative mortality and early results were significantly effective compared with coronary artery bypass grafting alone.

title: Results of coronary artery bypass grafting alone and combined with surgical ventricular reconstruction for XXXX .

answer: @entity1


abstract: OBJECTIVE: To develop and validate a clinical risk score predictive of risk for @entity2 for Asia. METHODS: A prospective, cross-sectional and multicentre study was carried out in tertiary hospitals in 11 Asian cities. The subjects comprise 2752 asymptomatic @entity0 undergoing screening colonoscopy. From a development set of 860 asymptomatic subjects undergoing screening colonoscopy, multiple logistic regression was applied to identify significant risk factors for advanced @entity2 defined as invasive @entity3 or advanced @entity4 . The ORs for significant risk factors were utilised to develop a risk score ranging from 0 to 7 (Asia-Pacific Colorectal Screening (APCS) score). Three tiers of risk were arbitrarily defined: 0-1 'average risk' (AR); 2-3 'moderate risk' (MR); and 4-7 'high risk' (HR). Subjects undergoing screening colonoscopy between July 2006 and December 2007 were prospectively enrolled to form an independent validation group. Each subject had a personal APCS score calculated by summing the points attributed from the presence of risk factors in the individuals. The performance of the APCS score in predicting risk of advanced @entity1 was evaluated. RESULTS: There were 860 subjects in the derivation set and 1892 subjects in the validation set, with a baseline prevalence of advanced @entity1 of 4.5% and 3%, respectively. Applying the APCS stratification in the validation set, 559 subjects (29.5%) were in the AR tier, 966 subjects (51.1%) in the MR tier and 367 (19.4%) subjects in the HR tier. The prevalence of advanced @entity1 in the AR, MR and HR groups was 1.3, 3.2 and 5.2%, respectively. The subjects in the MR and HR tiers had 2.6-fold (95% CI 1.1 to 6.0) and 4.3-fold (95% CI 1.8 to 10.3) increased prevalence of advanced @entity1 , respectively, than those in the AR tier. CONCLUSIONS: The APCS score based on age, gender, family history and smoking is useful in selecting asymptomatic Asian subjects for priority of colorectal screening.

title: The Asia-Pacific Colorectal Screening score: a validated tool that stratifies risk for XXXX in asymptomatic Asian subjects.

answer: @entity2


abstract: The effects of intravenously administered @entity3 and of varying amounts of energy on metabolic rate were studied and potential mechanisms examined in 19 healthy 4- to 6-day-old preterm (30 to 32 weeks gestation) @entity0 . The @entity0 were randomized to three groups. Group 1 (n = 6) received nonprotein energy 38 kcal/kg/d; group 2 (n = 5), 64 kcal/kg/d; and group 3 (n = 8), 64 kcal/kg/d plus 1 to 2 g/kg/d crystalline @entity3 . Thirty-six hours after beginning the infusion, @entity1 consumption (VO2) was measured by indirect calorimetry for 5 to 6 hours. Simultaneously, urine was collected for urinary @entity2 excretion, which was determined using liquid chromatography with electrochemical detection. Serum @entity5 (T4) and @entity4 (T3) concentrations were determined by radioimmunoassay. Group 1 had lower VO2 and urinary @entity2 excretion than did groups 2 and 3, which did not differ. T4 and T3 were not different among the three groups. The demonstrated simultaneous changes in @entity6 and @entity2 excretion with varying energy intakes independent of age supports energy intake as a modulator of the sympathetic nervous system, which in turn controls metabolic rate. Moderate amounts of intravenously administered @entity3 do not appear to play an active role in this process; nor do they alter T3 and T4 valves. When VO2 increased with increasing energy intake, T3 and T4 were unaffected, supporting a passive role for thyroid hormones in diet-induced thermogenesis.

title: Intravenous energy and XXXX in the preterm newborn @entity0 : effects on metabolic rate and potential mechanisms of action.

answer: @entity3


abstract: The effects of intravenously administered @entity3 and of varying amounts of energy on metabolic rate were studied and potential mechanisms examined in 19 healthy 4- to 6-day-old preterm (30 to 32 weeks gestation) @entity0 . The @entity0 were randomized to three groups. Group 1 (n = 6) received nonprotein energy 38 kcal/kg/d; group 2 (n = 5), 64 kcal/kg/d; and group 3 (n = 8), 64 kcal/kg/d plus 1 to 2 g/kg/d crystalline @entity3 . Thirty-six hours after beginning the infusion, @entity1 consumption (VO2) was measured by indirect calorimetry for 5 to 6 hours. Simultaneously, urine was collected for urinary @entity2 excretion, which was determined using liquid chromatography with electrochemical detection. Serum @entity5 (T4) and @entity4 (T3) concentrations were determined by radioimmunoassay. Group 1 had lower VO2 and urinary @entity2 excretion than did groups 2 and 3, which did not differ. T4 and T3 were not different among the three groups. The demonstrated simultaneous changes in @entity6 and @entity2 excretion with varying energy intakes independent of age supports energy intake as a modulator of the sympathetic nervous system, which in turn controls metabolic rate. Moderate amounts of intravenously administered @entity3 do not appear to play an active role in this process; nor do they alter T3 and T4 valves. When VO2 increased with increasing energy intake, T3 and T4 were unaffected, supporting a passive role for thyroid hormones in diet-induced thermogenesis.

title: Intravenous energy and @entity3 in the preterm newborn XXXX : effects on metabolic rate and potential mechanisms of action.

answer: @entity0


abstract: PURPOSE: To evaluate effectiveness of fall-risk-assessment-based fall prevention for @entity1 rehabilitation inpatients. METHOD: A consecutive series of 232 @entity0 admitted for the first time to a subacute @entity1 -rehabilitation ward during 2010-2011 was studied in detail. The Assessment Sheet for Fall Prediction in @entity1 Inpatients (ASFPSI by Nakagawa et  al.) was used to assess fall-risk upon admission. Association of ASFPSI score and @entity0 characteristics with actual falls was statistically tested. Yearly incidence of falls per 1000 @entity2 ( @entity2 ) was retrospectively audited for the 2006-2014 period to evaluate effectiveness of fall-risk reduction measures. RESULTS: The observed incidence of falls over the detailed-study-period was 3.0/1000 @entity2 ; 39% of the fallers fell during the first week after admission. ASFPSI score was not significantly associated with falls. Longer hospital stay, left body-side affected and non-extreme @entity3 score (55-101) were associated with higher odds of fall. Introduction of fall-risk reduction measures followed by compulsory fall-risk assessment lead to incidence of falls dropping from 7.1/1000 @entity2 in 2006 to 2.8/1000 @entity2 in 2011 and remaining at that level until 2014. CONCLUSIONS: The fall-risk-assessment-based measures appear to have led to decreasing falls risk among post- @entity1 rehabilitation inpatients classified as being at high risk of falls. The fall prevention programme as a whole was successful. @entity0 with non-extreme level of functional independence should receive enhanced fall prevention. Implications for Rehabilitation Recognising the fall risk upon the @entity0 's admission is essential for preventing falls in rehabilitation wards. Assessing the fall risk is a team tasks and combines information from various sources. Assessing fall risk in @entity1 @entity0 using the assessment sheet by Nakagawa et  al. immediately upon admission systematically draws attention to the risk of falls in each individual @entity0 .

title: Effectiveness of a fall-risk reduction programme for inpatient rehabilitation after XXXX .

answer: @entity1


abstract: UNASSIGNED: Mechanisms behind the emergence of brown adipocyte-like (brite or beige) adipocytes within @entity4 ( @entity4 ) are of interest. @entity3 protein gene (Rb) haploinsufficiency associates in @entity0 with improved metabolic regulation linked to a greater capacity for @entity2 oxidation and thermogenesis in @entity4 . We aimed to explain a feasible mechanism of @entity4 -to-BAT remodeling in this model. Differentiated primary adipocytes and @entity10 -positive preadipocytes derived from adipose depots of Rb(+/-) @entity0 and wild-type siblings were compared. Primary white Rb(+/-) adipocytes displayed under basal conditions increased @entity1 uptake and an enhanced expression of brown adipocyte-related genes ( @entity8 , @entity6 , @entity13 , @entity7 , @entity5 ), but not of purported beige/brite transcriptional markers ( @entity11 , @entity16 , @entity12 , @entity15 , @entity17 , @entity14 ). Lack of induction of beige markers phenocopied results in @entity4 of adult Rb(+/-) @entity0 . Flow cytometry analysis evidenced an increased number of preadipocytes in @entity4 depots of Rb(+/-) @entity0 . @entity10 (+) preadipocytes from @entity4 of Rb(+/-) @entity0 displayed increased gene expression of several transcription factors common to the brown and beige adipogenic programs ( @entity7 , @entity8 , @entity6 ) and of receptors of bone morphogenetic proteins (BMPs); however, amongst the recently proposed beige markers, only @entity12 was upregulated. Adult Rb(+/-) @entity0 had increased circulating levels of @entity9 . These results indicate that preadipose cells resident in @entity4 depots of Rb(+/-) @entity0 retain an increased capacity for brown-like adipogenesis that appears to be different from beige adipogenesis, and suggest that the contribution of these precursors to the Rb(+/-) adipose phenotype is driven, at least in part, by interaction with @entity9 pathways. This article is protected by copyright. All rights reserved.

title: Cell-Autonomous Brown-Like Adipogenesis of Preadipocytes from XXXX Haploinsufficient @entity0 .

answer: @entity3


abstract: UNASSIGNED: Mechanisms behind the emergence of brown adipocyte-like (brite or beige) adipocytes within @entity4 ( @entity4 ) are of interest. @entity3 protein gene (Rb) haploinsufficiency associates in @entity0 with improved metabolic regulation linked to a greater capacity for @entity2 oxidation and thermogenesis in @entity4 . We aimed to explain a feasible mechanism of @entity4 -to-BAT remodeling in this model. Differentiated primary adipocytes and @entity10 -positive preadipocytes derived from adipose depots of Rb(+/-) @entity0 and wild-type siblings were compared. Primary white Rb(+/-) adipocytes displayed under basal conditions increased @entity1 uptake and an enhanced expression of brown adipocyte-related genes ( @entity8 , @entity6 , @entity13 , @entity7 , @entity5 ), but not of purported beige/brite transcriptional markers ( @entity11 , @entity16 , @entity12 , @entity15 , @entity17 , @entity14 ). Lack of induction of beige markers phenocopied results in @entity4 of adult Rb(+/-) @entity0 . Flow cytometry analysis evidenced an increased number of preadipocytes in @entity4 depots of Rb(+/-) @entity0 . @entity10 (+) preadipocytes from @entity4 of Rb(+/-) @entity0 displayed increased gene expression of several transcription factors common to the brown and beige adipogenic programs ( @entity7 , @entity8 , @entity6 ) and of receptors of bone morphogenetic proteins (BMPs); however, amongst the recently proposed beige markers, only @entity12 was upregulated. Adult Rb(+/-) @entity0 had increased circulating levels of @entity9 . These results indicate that preadipose cells resident in @entity4 depots of Rb(+/-) @entity0 retain an increased capacity for brown-like adipogenesis that appears to be different from beige adipogenesis, and suggest that the contribution of these precursors to the Rb(+/-) adipose phenotype is driven, at least in part, by interaction with @entity9 pathways. This article is protected by copyright. All rights reserved.

title: Cell-Autonomous Brown-Like Adipogenesis of Preadipocytes from @entity3 Haploinsufficient XXXX .

answer: @entity0


abstract: OBJECTIVE: To determine whether anatomical modification of sympathectomy diminishes severe postoperative compensatory @entity2 . @entity0 AND METHODS: From January 1, 2000, to June 1, 2001, we prospectively studied 10 consecutive @entity0 with primary palmar @entity2 , aged 14 to 42 years. Medical therapy had failed in all @entity0 . A preoperative and postoperative evaluation and thermoregulatory sweat testing were conducted in all @entity0 . All @entity0 underwent sympathotomy (bilateral simple disconnection) of the second thoracic ganglion input into the brachial plexus, and no sympathetic ganglia were violated. RESULTS: In the 10 @entity0 , all 20 upper extremities improved postoperatively: 11 (55%) had near-complete cessation of palmar sweating, 8 (40%) had marked reduction in sweating, and 1 (5%) had delayed onset but full sweating at the end of the thermoregulatory sweat test. No intraoperative complications of @entity3 or @entity4 occurred. Importantly, there were no moderate or severe @entity1 . CONCLUSION: Sympathotomy to disconnect T2 ganglion input into the brachial plexus produces excellent results in the treatment of primary palmar @entity2 and may lower the severity of @entity1 . Long-term durability of the procedure requires further follow-up.

title: Sympathotomy instead of sympathectomy for palmar XXXX : minimizing postoperative compensatory @entity2 .

answer: @entity2


abstract: OBJECTIVE: To determine whether anatomical modification of sympathectomy diminishes severe postoperative compensatory @entity2 . @entity0 AND METHODS: From January 1, 2000, to June 1, 2001, we prospectively studied 10 consecutive @entity0 with primary palmar @entity2 , aged 14 to 42 years. Medical therapy had failed in all @entity0 . A preoperative and postoperative evaluation and thermoregulatory sweat testing were conducted in all @entity0 . All @entity0 underwent sympathotomy (bilateral simple disconnection) of the second thoracic ganglion input into the brachial plexus, and no sympathetic ganglia were violated. RESULTS: In the 10 @entity0 , all 20 upper extremities improved postoperatively: 11 (55%) had near-complete cessation of palmar sweating, 8 (40%) had marked reduction in sweating, and 1 (5%) had delayed onset but full sweating at the end of the thermoregulatory sweat test. No intraoperative complications of @entity3 or @entity4 occurred. Importantly, there were no moderate or severe @entity1 . CONCLUSION: Sympathotomy to disconnect T2 ganglion input into the brachial plexus produces excellent results in the treatment of primary palmar @entity2 and may lower the severity of @entity1 . Long-term durability of the procedure requires further follow-up.

title: Sympathotomy instead of sympathectomy for palmar @entity2 : minimizing postoperative compensatory XXXX .

answer: @entity2


abstract: AIM: The current outcome of @entity3 ( @entity3 ) @entity0 in the Maastricht region was analysed with the prospect of implementing extracorporeal cardiopulmonary resuscitation (E-CPR). METHODS: A retrospective analysis of adult @entity0 who were resuscitated for @entity3 during a 24-month period was performed. RESULTS: 195 @entity0 (age 66 [57-75] years, 82   % male) were resuscitated for @entity3 by the emergency medical services and survived to admission at the emergency department. Survival to hospital discharge was 46.2   %. Notable differences between non-survivors and survivors were observed and included: age (70 [58-79] years) vs. (63 [55-72] years, p   =   0.01), @entity2 (18 vs. 7   %, p   =   0.02), shockable rhythm (67 vs. 99   %, p   <   0.01), and return of spontaneous circulation (ROSC) at departure from the site of the arrest (46 vs. 99   %, p   <   0.01) and on arrival to the emergency department (43 vs. 98   %, p   <   0.01), respectively. @entity4 was diagnosed in 32   % of non-survivors vs. 59   % among survivors, p   <   0.01. Therapeutic @entity5 was provided in non-survivors (20   %) vs. survivors (43   %), p   <   0.01. Percutaneous coronary intervention (PCI) was performed in 14   % of non-survivors while 52   % of survivors received PCI (p   <   0.01). No statistical significance was observed in terms of gender, witnessed arrest, bystander CPR, or automated external defibrillator deployed among the cohort. At hospital discharge, moderately severe @entity1 was present in six survivors. CONCLUSION: These observations are compatible with the notion that a shockable rhythm, ROSC, and post-arrest care improve survival outcome. Potentially, initiating E-CPR in the resuscitation phase in @entity0 with a shockable rhythm and no ROSC might serve as a bridge to definite treatment and improve survival outcome.

title: XXXX : the prospect of E-CPR in the Maastricht region.

answer: @entity3


abstract: Phagocytic and bactericidal assays showed that a close correlation was present between bactericidal activity and neutrophil chemiluminescence (PMN-CL) (r = 0.81; p less than 0.01). This suggested that the microbicidal action of the neutrophil depends metabolically on the generation of oxygenating agents. PMN-CL and @entity6 ( @entity6 ) were measured in 36 burned @entity0 . The levels of serum @entity1 (Tf) were examined simultaneously by nephelometric method in order to determine the correlation between humoral-phagocyte axis of immune system and nutritional status. It was found that PMN-CL and @entity6 were generally lower in the greater than 35% TBSA burn group (PMN-CL, 1.85 +/- 0.21 cpm X 10(3), @entity6 , 0.69 +/- 0.06) compared with control subjects (PMN-CL, 3.55 +/- 0.15 cpm X 10(3), @entity6 , 1.05 +/- 0.04). It suggested that both neutrophil oxygenation activity and opsonic activity were @entity2 following severe @entity7 . PMN-CL was higher in the smaller than 30% TBSA burn group during @entity3 phase as compared with control subjects (5.61 +/- 0.26 cpm X 10(3) vs. 3.55 +/- 01.5 cpm X 10(3); p less than 0.01). It remained high in @entity0 with persistent @entity3 , but fell to normal if appropriate therapy was instituted. This result indicated that the neutrophils of the majority of @entity0 with minor @entity7 during @entity5 were in an activated state both metabolically and functionally. The occurrence of @entity4 was associated with a marked lowering of PMN-CL and @entity6 values, but no difference was noted before and after the development of @entity4 . The incidence of @entity4 was 85.7% when PMN-CL was lower than 2 cpm X 10(3).(ABSTRACT TRUNCATED AT 250 WORDS)

title: Neutrophil chemiluminescence in burned XXXX .

answer: @entity0


abstract: BACKGROUND: Polarization of @entity2 infiltrating macrophages is associated with the prognosis of solid @entity2 and correlates with the occurrence of lymph node @entity1 in @entity4 ( @entity4 ). Early stage (T1/T2, N0) @entity4 are characterized by a good prognosis and can be cured by surgery. The postoperative regime usually contains no adjuvant radio-/chemotherapy. The current pilot study was conducted to elucidate whether macrophage polarization in @entity2 resection specimens and diagnostic biopsies of early stage @entity4 is associated with @entity2 outcome. METHODS: @entity0 with T1/T2, N0, and R0>5mm @entity4 without adjuvant therapy and 3-year follow-up after @entity2 resection were retrospectively selected. Tissue microarrays (TMA) containing diagnostic biopsies (n=17) and @entity2 resection specimens (n=17) were processed for immunohistochemistry in this pilot study to detect @entity3 -, @entity5 -, @entity6 - and @entity7 -positive macrophages. Samples were digitized, and the expression of macrophage markers was quantitatively analyzed. RESULTS: High infiltration of M2 polarized macrophages correlated with poor @entity2 outcome in early stage (T1/T2, N0) @entity4 . This correlation was observed in @entity2 resection specimens, but was also observed in diagnostic biopsies. M2 macrophage polarization in biopsies - but not in @entity2 resection samples - correlated with high scores in @entity2 grading. CONCLUSION: Macrophage polarization in early stage @entity4 is a potential prognostic marker for @entity2 outcome. The correlation of M2 polarized macrophages with @entity2 outcome can already be detected in the initial biopsies. Furthermore, M2 polarization of macrophages in biopsies is associated with an increased dedifferentiation.

title: Prognostic significance of macrophage polarization in early stage XXXX .

answer: @entity4


abstract: OBJECTIVE: To evaluate the efficacy and adverse effects of oral @entity4 for treatment of periocular @entity7 . METHODS: @entity0 were treated with oral @entity4 3 times daily, with outpatient monitoring of adverse effects. The starting dosage was 0.5 mg/kg/d for 1 week, then 1 mg/kg/d for the following week, then 2 mg/kg/d for the remaining duration of treatment. Serial examinations and external photography documented the size of the @entity5 . Complete ophthalmic examinations included assessing for @entity6 with cycloplegic refraction and visual diagnostic testing. @entity6 was treated with part-time occlusion therapy. RESULTS: Nineteen periocular @entity5 from 17 @entity0 (71% @entity0 ) were studied. The median age at the start of treatment was 4.5 months (interquartile range, 2.2-5.6 months). The median treatment duration was 6.8 months (interquartile range, 4.1-7.2 months). Treatment with oral @entity4 reduced the size of all @entity5 . Median change in the surface area was 61% (interquartile range, 32%-64%) of the original size. Mild rebound growth that did not necessitate retreatment was found in 2 @entity0 (12%). One @entity0 (6%) experienced a benign episode of @entity3 . Seven @entity0 (41%) had @entity6 . CONCLUSIONS: Oral @entity4 for treatment of infantile @entity5 was effective in all @entity0 , with 33% reduction in @entity2 and 39% reduction in surface area. Vision equalized in all but 1 @entity0 , who receives ongoing @entity6 therapy. Our results suggest that early treatment with @entity4 is remarkably effective in treating and preventing @entity1 associated with periocular infantile @entity5 .

title: Oral XXXX for treatment of periocular infantile @entity5 .

answer: @entity4


abstract: OBJECTIVE: To evaluate the efficacy and adverse effects of oral @entity4 for treatment of periocular @entity7 . METHODS: @entity0 were treated with oral @entity4 3 times daily, with outpatient monitoring of adverse effects. The starting dosage was 0.5 mg/kg/d for 1 week, then 1 mg/kg/d for the following week, then 2 mg/kg/d for the remaining duration of treatment. Serial examinations and external photography documented the size of the @entity5 . Complete ophthalmic examinations included assessing for @entity6 with cycloplegic refraction and visual diagnostic testing. @entity6 was treated with part-time occlusion therapy. RESULTS: Nineteen periocular @entity5 from 17 @entity0 (71% @entity0 ) were studied. The median age at the start of treatment was 4.5 months (interquartile range, 2.2-5.6 months). The median treatment duration was 6.8 months (interquartile range, 4.1-7.2 months). Treatment with oral @entity4 reduced the size of all @entity5 . Median change in the surface area was 61% (interquartile range, 32%-64%) of the original size. Mild rebound growth that did not necessitate retreatment was found in 2 @entity0 (12%). One @entity0 (6%) experienced a benign episode of @entity3 . Seven @entity0 (41%) had @entity6 . CONCLUSIONS: Oral @entity4 for treatment of infantile @entity5 was effective in all @entity0 , with 33% reduction in @entity2 and 39% reduction in surface area. Vision equalized in all but 1 @entity0 , who receives ongoing @entity6 therapy. Our results suggest that early treatment with @entity4 is remarkably effective in treating and preventing @entity1 associated with periocular infantile @entity5 .

title: Oral @entity4 for treatment of periocular infantile XXXX .

answer: @entity5


abstract: OBJECTIVE: To report a new manifestation of the rare connective tissue disorder @entity11 in the absence of skin and soft-tissue abnormalities and with bilateral, giant fusiform @entity5 . DESIGN: Case report. SETTING: University teaching hospital. @entity0 : A 67-year-old @entity0 with a history of @entity2 presented to medical attention after a @entity9 . Imaging revealed incidental, bilateral, giant fusiform @entity5 at their junction of the circle of Willis. There was also @entity4 of the left main @entity6 and @entity4 of the aorta and bilateral iliac arteries, suggestive of @entity11 . RESULTS: The @entity0 's @entity9 was attributed to transient complete @entity7 for which a permanent pacemaker was placed. The @entity0 started taking @entity3 for @entity1 prevention and @entity10 for blood pressure control. CONCLUSIONS: To our knowledge, we present the first case of @entity11 with marked bilateral intracranial artery dilation in the absence of concurrent skin and soft tissue abnormalities. Workup may include systemic vascular imaging to characterize the extent of disease. Antiplatelet therapy can be used for @entity1 prevention by reducing the risk of clot formation in ectatic vessels with altered hemodynamics and subsequent @entity8 . @entity10 is known to inhibit transforming growth factor b signaling and may be a specific modulator of disease expression in this syndrome.

title: XXXX with @entity5 : a case report.

answer: @entity11


abstract: OBJECTIVE: To report a new manifestation of the rare connective tissue disorder @entity11 in the absence of skin and soft-tissue abnormalities and with bilateral, giant fusiform @entity5 . DESIGN: Case report. SETTING: University teaching hospital. @entity0 : A 67-year-old @entity0 with a history of @entity2 presented to medical attention after a @entity9 . Imaging revealed incidental, bilateral, giant fusiform @entity5 at their junction of the circle of Willis. There was also @entity4 of the left main @entity6 and @entity4 of the aorta and bilateral iliac arteries, suggestive of @entity11 . RESULTS: The @entity0 's @entity9 was attributed to transient complete @entity7 for which a permanent pacemaker was placed. The @entity0 started taking @entity3 for @entity1 prevention and @entity10 for blood pressure control. CONCLUSIONS: To our knowledge, we present the first case of @entity11 with marked bilateral intracranial artery dilation in the absence of concurrent skin and soft tissue abnormalities. Workup may include systemic vascular imaging to characterize the extent of disease. Antiplatelet therapy can be used for @entity1 prevention by reducing the risk of clot formation in ectatic vessels with altered hemodynamics and subsequent @entity8 . @entity10 is known to inhibit transforming growth factor b signaling and may be a specific modulator of disease expression in this syndrome.

title: @entity11 with XXXX : a case report.

answer: @entity5


abstract: AIMS: @entity6 ( @entity6 ) aggravates @entity4 by inducing @entity2 oxidase (NOX)-dependent oxidative stress. @entity15 [ @entity12 -(1-7)], which counter-regulates @entity6 , has been evidenced to protect against @entity4 . The NOD-like receptor family pyrin domain containing 3 ( @entity10 ) inflammasome, being activated by reactive @entity0 species (ROS), is identified as a novel mechanism of liver @entity1 . However, whether the @entity10 inflammasome involves in regulation of @entity6 -induced @entity4 remains unclear. This study investigates the different effects of the @entity6 and @entity12 -(1-7) on collagen synthesis by regulating the @entity10 inflammasome/Smad pathway via redox balance modulation. RESULTS: In vivo, @entity12 -(1-7) improved bile duct ligation-induced @entity4 , reduced @entity9 content, protein levels of @entity14 , and the @entity10 inflammasome, whereas it increased @entity5 ( @entity11 ) and @entity13 ( @entity13 ) antioxidant response element (ARE). In vitro, @entity12 II treatment elevated @entity14 protein expression and ROS production in hepatic stellate cells (HSCs), whereas it inhibited @entity11 and @entity13 -ARE, resulting in the activation of the @entity10 inflammasome in the mitochondria of HSCs. @entity10 depletion inhibited @entity6 -induced collagen synthesis. Furthermore, @entity6 increased @entity10 and @entity3 levels by activating the @entity7 ( @entity7 )/ @entity8 /NF-kB pathway. Treatment with antioxidants, @entity14 small interference RNA (siRNA), or @entity13 activator inhibited @entity6 -induced @entity10 inflammasome activation and collagen synthesis. In contrast, the action of @entity12 -(1-7) opposed the effects of @entity6 . Innovation and Conclusions: @entity12 -(1-7) improved liver @entity1 by regulating @entity10 inflammasome activation induced by @entity12 II-mediated ROS via redox balance modulation. Antioxid. Redox Signal. 00, 000-000.

title: Angiotensin-(1-7) Improves @entity4 by Regulating the XXXX Inflammasome via Redox Balance Modulation.

answer: @entity10


abstract: AIMS: @entity6 ( @entity6 ) aggravates @entity4 by inducing @entity2 oxidase (NOX)-dependent oxidative stress. @entity15 [ @entity12 -(1-7)], which counter-regulates @entity6 , has been evidenced to protect against @entity4 . The NOD-like receptor family pyrin domain containing 3 ( @entity10 ) inflammasome, being activated by reactive @entity0 species (ROS), is identified as a novel mechanism of liver @entity1 . However, whether the @entity10 inflammasome involves in regulation of @entity6 -induced @entity4 remains unclear. This study investigates the different effects of the @entity6 and @entity12 -(1-7) on collagen synthesis by regulating the @entity10 inflammasome/Smad pathway via redox balance modulation. RESULTS: In vivo, @entity12 -(1-7) improved bile duct ligation-induced @entity4 , reduced @entity9 content, protein levels of @entity14 , and the @entity10 inflammasome, whereas it increased @entity5 ( @entity11 ) and @entity13 ( @entity13 ) antioxidant response element (ARE). In vitro, @entity12 II treatment elevated @entity14 protein expression and ROS production in hepatic stellate cells (HSCs), whereas it inhibited @entity11 and @entity13 -ARE, resulting in the activation of the @entity10 inflammasome in the mitochondria of HSCs. @entity10 depletion inhibited @entity6 -induced collagen synthesis. Furthermore, @entity6 increased @entity10 and @entity3 levels by activating the @entity7 ( @entity7 )/ @entity8 /NF-kB pathway. Treatment with antioxidants, @entity14 small interference RNA (siRNA), or @entity13 activator inhibited @entity6 -induced @entity10 inflammasome activation and collagen synthesis. In contrast, the action of @entity12 -(1-7) opposed the effects of @entity6 . Innovation and Conclusions: @entity12 -(1-7) improved liver @entity1 by regulating @entity10 inflammasome activation induced by @entity12 II-mediated ROS via redox balance modulation. Antioxid. Redox Signal. 00, 000-000.

title: Angiotensin-(1-7) Improves XXXX by Regulating the @entity10 Inflammasome via Redox Balance Modulation.

answer: @entity4


abstract: In an attempt to assess the efficacy of thrombolytic infusions for @entity1 , a questionnaire was distributed to 142 vascular surgeons. Data from 45 respondents who had experience with thrombolytic infusion in 623 @entity0 were reviewed. A successful outcome was obtained in 313 of 623 @entity0 (50.2%). Morbidity was significant, with @entity3 requiring transfusion or operation in 125 cases (20.1%) and major amputation in 103 cases (16.5%). There were nine strokes associated with thrombolytic infusion (1.4%), six of which were fatal. Sixteen @entity2 were associated with thrombolytic therapy, for a mortality rate of 2.5% (16 of 623 @entity0 ). Analysis of results by grouping centers according to numbers of lytic infusions failed to show significant correlation with center experience. Furthermore, morbidity and mortality were seen in centers with both limited and extensive experience with thrombolytic infusion. The initial enthusiasm for thrombolytic infusion to treat @entity1 is not substantiated by our data. Carefully controlled prospective trials are needed before this method can be offered as an alternative to arterial reconstruction.

title: Use and limitations of thrombolytic therapy in the treatment of peripheral XXXX : results of a multi-institutional questionnaire.

answer: @entity1


abstract: SUMMARY: The incidence of subclinical @entity2 in Simmental and Simmental-Red Holstein @entity1 in relation to the @entity1 major histocompatibility complex ( @entity4 ) was investigated. Quarter milk samples of 166 @entity1 consisting of fifteen halfsib groups of different ages and lactation stages were analysed for somatic cell counts ( @entity3 ) and bacteriological @entity0 . From these data the udder health status (UHS) of the animal was determined. Each @entity1 was typed serologically for @entity4 class I and class II specificities. The statistical evaluation for UHS was performed using a logistic regression model. The effect of @entity4 on @entity3 was estimated by least square analysis. Animals carrying the @entity4 class II haplotype "b" were significantly more affected by subclinical @entity2 than those without this haplotype. Breed group showed a significant influence on both UHS and corrected mean logSCC (P < 0.0001 resp. P < 0.05). Lactation stage had a significant effect on @entity3 but only a weak influence on UHS (P < 0.0001 resp. P < 0.13). ZUSAMMENFASSUNG: M  gliche Assoziation zwischen dem bovinen Haupthistokompatibilit  tskomplex und subklinischer @entity2 In dieser Studie wurde die Beziehung zwischen dem bovinen Histokompatibilit  tskomplex ( @entity4 ) und der Pr  valenz subklinischer @entity2 bei Simmentaler und mit Red Holstein eingekreuzten Simmentaler K  hen untersucht. Bei 166 K  hen, aus 15 Halbgeschwistergruppen, unterschiedlichen Alters und in verschiedenen Laktationsstadien, wurden Milchproben entnommen und auf Zellzahl ( @entity3 ) und bakterielle Infektion untersucht. Aus diesen Daten wurde ein Eutergesundheitsstatus (UHS) definiert. Jede Kuh wurde serologisch f  r @entity4 Klasse I und Klasse II Spezifit  ten typisiert. Die statistische Auswertung f  r den UHS erfolgte mit einem logistischen Regressionsmodel. Der Einflu   von @entity4 -Haplotypen auf @entity3 wurde mit der Least Square Analyse ermittelt. Tiere mit dem Klasse II Allel "b" zeigten mehr Euterprobleme als K  he ohne dieses Allel. Die Rassegruppe   bte sowohl auf den UHS wie auch auf den korrigierten Mittelwert der Zellzahlen einen signifikanten Einflu   aus (P < 0.0001 resp. P < 0.05). Der Effekt des Laktationsstadiums auf die Zellzahl war signifikant, aber f  r den UHS wurde nur ein schwacher Einflu   des Laktationsstadiums festgestellt (P < 0.0001 resp. P < 0.13).

title: Possible association between a serologically detected haplotype of the XXXX Major Histocompatibility Complex and subclinical @entity2 .

answer: @entity1


abstract: SUMMARY: The incidence of subclinical @entity2 in Simmental and Simmental-Red Holstein @entity1 in relation to the @entity1 major histocompatibility complex ( @entity4 ) was investigated. Quarter milk samples of 166 @entity1 consisting of fifteen halfsib groups of different ages and lactation stages were analysed for somatic cell counts ( @entity3 ) and bacteriological @entity0 . From these data the udder health status (UHS) of the animal was determined. Each @entity1 was typed serologically for @entity4 class I and class II specificities. The statistical evaluation for UHS was performed using a logistic regression model. The effect of @entity4 on @entity3 was estimated by least square analysis. Animals carrying the @entity4 class II haplotype "b" were significantly more affected by subclinical @entity2 than those without this haplotype. Breed group showed a significant influence on both UHS and corrected mean logSCC (P < 0.0001 resp. P < 0.05). Lactation stage had a significant effect on @entity3 but only a weak influence on UHS (P < 0.0001 resp. P < 0.13). ZUSAMMENFASSUNG: M  gliche Assoziation zwischen dem bovinen Haupthistokompatibilit  tskomplex und subklinischer @entity2 In dieser Studie wurde die Beziehung zwischen dem bovinen Histokompatibilit  tskomplex ( @entity4 ) und der Pr  valenz subklinischer @entity2 bei Simmentaler und mit Red Holstein eingekreuzten Simmentaler K  hen untersucht. Bei 166 K  hen, aus 15 Halbgeschwistergruppen, unterschiedlichen Alters und in verschiedenen Laktationsstadien, wurden Milchproben entnommen und auf Zellzahl ( @entity3 ) und bakterielle Infektion untersucht. Aus diesen Daten wurde ein Eutergesundheitsstatus (UHS) definiert. Jede Kuh wurde serologisch f  r @entity4 Klasse I und Klasse II Spezifit  ten typisiert. Die statistische Auswertung f  r den UHS erfolgte mit einem logistischen Regressionsmodel. Der Einflu   von @entity4 -Haplotypen auf @entity3 wurde mit der Least Square Analyse ermittelt. Tiere mit dem Klasse II Allel "b" zeigten mehr Euterprobleme als K  he ohne dieses Allel. Die Rassegruppe   bte sowohl auf den UHS wie auch auf den korrigierten Mittelwert der Zellzahlen einen signifikanten Einflu   aus (P < 0.0001 resp. P < 0.05). Der Effekt des Laktationsstadiums auf die Zellzahl war signifikant, aber f  r den UHS wurde nur ein schwacher Einflu   des Laktationsstadiums festgestellt (P < 0.0001 resp. P < 0.13).

title: Possible association between a serologically detected haplotype of the @entity1 Major Histocompatibility Complex and subclinical XXXX .

answer: @entity2


abstract: From October 1981 to October 1984, 42 consecutive @entity0 with locally advanced unresectable or metastatic transitional cell @entity7 were treated with cis- @entity4 50 mg/m2 i.v. and @entity3 50 mg/m2 i.v. day 1, and @entity5 500 mg/m2 i.v. and @entity6 100 mg/m2 days 1 and 8, every 3 weeks. In the 36 evaluable @entity0 , 4 complete remissions and 15 partial remissions were noted (52.7% response rate). Of the 12 @entity0 with previously untreated, locally advanced @entity2 , 8 responded, with 3 pathologically confirmed complete remissions. @entity1 was moderate. Median survival was 44 weeks. This 4-drug combination had significant palliative activity in our @entity0 population. Its role in the preoperative setting deserves further evaluation.

title: Combination chemotherapy with @entity5 , XXXX , cis-platinum and @entity6 in advanced transitional cell @entity7 .

answer: @entity3


abstract: From October 1981 to October 1984, 42 consecutive @entity0 with locally advanced unresectable or metastatic transitional cell @entity7 were treated with cis- @entity4 50 mg/m2 i.v. and @entity3 50 mg/m2 i.v. day 1, and @entity5 500 mg/m2 i.v. and @entity6 100 mg/m2 days 1 and 8, every 3 weeks. In the 36 evaluable @entity0 , 4 complete remissions and 15 partial remissions were noted (52.7% response rate). Of the 12 @entity0 with previously untreated, locally advanced @entity2 , 8 responded, with 3 pathologically confirmed complete remissions. @entity1 was moderate. Median survival was 44 weeks. This 4-drug combination had significant palliative activity in our @entity0 population. Its role in the preoperative setting deserves further evaluation.

title: Combination chemotherapy with @entity5 , @entity3 , cis-platinum and @entity6 in advanced transitional cell XXXX .

answer: @entity7


abstract: From October 1981 to October 1984, 42 consecutive @entity0 with locally advanced unresectable or metastatic transitional cell @entity7 were treated with cis- @entity4 50 mg/m2 i.v. and @entity3 50 mg/m2 i.v. day 1, and @entity5 500 mg/m2 i.v. and @entity6 100 mg/m2 days 1 and 8, every 3 weeks. In the 36 evaluable @entity0 , 4 complete remissions and 15 partial remissions were noted (52.7% response rate). Of the 12 @entity0 with previously untreated, locally advanced @entity2 , 8 responded, with 3 pathologically confirmed complete remissions. @entity1 was moderate. Median survival was 44 weeks. This 4-drug combination had significant palliative activity in our @entity0 population. Its role in the preoperative setting deserves further evaluation.

title: Combination chemotherapy with XXXX , @entity3 , cis-platinum and @entity6 in advanced transitional cell @entity7 .

answer: @entity5


abstract: From October 1981 to October 1984, 42 consecutive @entity0 with locally advanced unresectable or metastatic transitional cell @entity7 were treated with cis- @entity4 50 mg/m2 i.v. and @entity3 50 mg/m2 i.v. day 1, and @entity5 500 mg/m2 i.v. and @entity6 100 mg/m2 days 1 and 8, every 3 weeks. In the 36 evaluable @entity0 , 4 complete remissions and 15 partial remissions were noted (52.7% response rate). Of the 12 @entity0 with previously untreated, locally advanced @entity2 , 8 responded, with 3 pathologically confirmed complete remissions. @entity1 was moderate. Median survival was 44 weeks. This 4-drug combination had significant palliative activity in our @entity0 population. Its role in the preoperative setting deserves further evaluation.

title: Combination chemotherapy with @entity5 , @entity3 , cis-platinum and XXXX in advanced transitional cell @entity7 .

answer: @entity6


abstract: BACKGROUND: Neonatal inspiratory stridor is an important examination finding that requires immediate and adequate evaluation of the underlying etiology. Depending on the severity of the @entity4 or absence of associated symptoms such as @entity3 and feeding problems, early initiation of a complete diagnostic workup can be crucial. The most common cause of neonatal inspiratory stridor is @entity5 , however, several differential diagnoses need to be investigated. More rare causes include oral or laryngeal masses. @entity2 of the head and neck region are one of the most unusual causes of @entity3 during the neonatal period. We present a case of a mature @entity2 in the oropharynx presenting with @entity4 in a newborn @entity0 . CASE PRESENTATION: A four-day-old female Caucasian @entity0 was admitted to the neonatal intensive care unit of our hospital because of inspiratory stridor and profound desaturations while feeding. Diagnostic workup by ultrasound, magnetic resonance imaging and flexible endoscopy revealed a pediculated lesion in the pharyngeal region causing intermittent complete @entity4 . The mass was surgically removed by transoral laser resection on the seventh day of life. Histological evaluation was consistent with a mature @entity2 without any signs of @entity1 . The further hospital course was uneventful, routine follow-up examinations at 3, 6 and 9  months of age showed no evidence of @entity1 recurrence. CONCLUSION: Neonatal stridor is a frequent symptom in the neonatal period and is mostly caused by non-life-threatening pathologies. On rare occasions, however, the underlying conditions are more critical. A careful stepwise diagnostic investigation to rule out these conditions, to identify rare causes and to initiate early treatment is therefore warranted.

title: An unusual cause of inspiratory stridor in the newborn: congenital pharyngeal XXXX - a case report.

answer: @entity2